作者
Naveed Sattar, Matthew MY Lee, Søren L Kristensen, Kelley RH Branch, Stefano Del Prato, Nardev S Khurmi, Carolyn SP Lam, Renato D Lopes, John JV McMurray, Richard E Pratley, Julio Rosenstock, Hertzel C Gerstein
发表日期
2021/10/1
来源
The lancet Diabetes & endocrinology
卷号
9
期号
10
页码范围
653-662
出版商
Elsevier
简介
Background
GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes.
Methods
We did a meta-analysis, including new data from AMPLITUDE-O, using a random effects model to estimate overall hazard ratio (HR) for MACE; its components; all-cause mortality; hospital admission for heart failure; a composite kidney outcome consisting of development of macroalbuminuria, doubling of serum creatinine, or at least 40% decline in estimated glomerular filtration rate (eGFR), kidney replacement therapy, or death due to kidney disease; worsening of …
学术搜索中的文章
N Sattar, MMY Lee, SL Kristensen, KRH Branch… - The lancet Diabetes & endocrinology, 2021